- Home
- / Rapport Therapeutics
Rapport Therapeutics
Stock Price
$25.4
2024-10-29
Market Capitalization
$927.9 M
2024-10-29
Rapport Therapeutics Summary
Company Summary
- Overview
- Rapport Therapeutics is a biotechnology company that develops medicines for neurological disorders. It develops medicines that modulate neurotransmitter receptors to treat drug-resistant seizures.
- Type
- Public
- Status
- Active
- Founded
- 2022
- HQ
- Boston, MA, US | view all locations
- Website
- https://www.rapportrx.com
- Cybersecurity rating
Table of Contents
Key People
David Bredt, Founder, Chief Scientific Officer
Brad Galer, Chief Medical Officer
Swamy Yeleswaram, Chief Development Officer
LocationsView all
2 locations detected
Boston, MA HQ
United States
1325 Boylston St #401
San Diego, CA
United States
3210 Merryfield Row, Office 2516
Rapport Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $20.0M
- Net income (Q1, 2026)
- ($19.9M)
- Cash (Q1, 2026)
- $78.1M
- EBIT (Q1, 2026)
- ($24.2M)
- Enterprise value
- $860.7M